Almost a decade ago a team of oncology, bioinformatics, artificial intelligence and computational experts from the National Cancer Institute, prestigious hospitals, and universities were gathered to create a company that would move beyond the promise of precision medicine. This team understood that genomic testing alone would provide only one piece of a very complex puzzle. They knew that for the patient to truly benefit, many more factors would need to be taken into account and combined to give a complete picture of the patient, their cancer, and the therapies that would provide for the most optimal outcome. Factors that were not being considered or reported in standard testing lab reports alone.
The result of their efforts is Perthera, Inc., and the revolutionary product is the Perthera Precision Oncology Platform which produces the Perthera Analysis.
“George Mason researcher Emanuel “Chip” Petricoin helped found Perthera Inc., a McLean-based company, which uses technology to pinpoint cancer treatments in individual patients. This process is known as precision cancer analysis. Now, the company is getting a boost from Pilot Growth Equity, a technology growth equity firm that sees great potential in this technology.
Such innovation, which was once isolated to the lab, is now creating opportunities for successful businesses that solve serious problems and generate economic growth.”
Perthera is a privately held corporation with experienced leadership and an advisory board that includes key thought leaders, researchers, and practitioners in artificial intelligence and precision medicine.
If you are interested in learning more about Perthera, or for financial or investment inquiries, please contact us at +1 (508) 397-8885